SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2024
(Name of Registrant)
IDA Business Park
Bray, County Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos.
333-182279, 333-195232 and 333-253070) and Registration Statements on Form F-3 (File Nos. 333-264992, 333-267160, 333-279017 and 333-280391).
EXPLANATORY NOTE
On August 20, 2024 the Company issued a press release announcing the appointment of David Ouston as Biosensor
Marketing Director. The press release is filed herewith as Exhibit 99.1.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
| |
TRINITY BIOTECH PLC
|
|
| |
|
Trinity Biotech plc
|
|
| |
|
(Registrant)
|
|
| |
|
|
|
| |
By:
|
/s/ John Gillard
|
|
| |
|
John Gillard
|
|
| |
|
Chief Executive Officer
|
|
Date: August 21, 2024
Exhibit 99.1
|
Contact:
|
Trinity Biotech plc
Gary Keating
(353)-1-2769800
|
LifeSci Partners, LLC
Eric Ribner
(1)-646-751-4363
investorrelations@trinitybiotech.com
RedChip Companies Inc.
Dave Gentry, CEO
(1)-407-644-4256
TRIB@redchip.com
|
Trinity Biotech Appoints Diabetes Care Veteran as Biosensor
Marketing Director
DUBLIN, Ireland (August 20, 2024) - Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions,
including wearable biosensors, today announces the appointment of David Ouston as Biosensor Marketing Director. Mr. Ouston brings a wealth of commercial experience driving the growth of glucose monitoring devices at large, established companies
across global markets.
John Gillard, President and Chief Executive Officer of Trinity Biotech, said, “We remain focused on our innovative, needle-free, reusable continuous glucose monitoring (CGM) technology as a key long-term growth driver
for Trinity Biotech, and we are delighted to welcome David as a strategic appointment to our expanding team to help further this mission. His extensive global leadership experience in promotion and market access strategies for diabetes management
devices and digital solutions will be a strong asset for Trinity Biotech as we prepare the roll out of our own CGM in rapidly growing diabetes and wellness markets.”
Commenting on his appointment, Mr. Ouston said, “I am thrilled to join Trinity Biotech to help realize its vision for an accessible and innovative CGM in global markets. Trinity’s device offers promising and exciting
innovation in wearable biosensor technology and wellness analytics that can benefit more people globally to improve public health. I’m excited to work with this impressive team in delivering a truly disruptive and valuable solution to markets
globally.”
Mr. Ouston’s career spans 16 years in the glucose monitoring and diabetes health sectors, including global and EMEA regional marketing roles at Johnson & Johnson and LifeScan, where he led innovations in the OneTouch
glucose monitoring portfolio. Previously, he held marketing positions at private healthcare provider Bupa, where he supported the promotion of their global healthcare brand. Mr. Ouston holds a Bachelor of Arts Degree in Business Administration from
Brunel University in the U.K.
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited
to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity
Biotech claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterised by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of
similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on our purchase of the assets of
Waveform, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the
company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence
on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of
defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of
infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended
December 31, 2023 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not
undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires,
manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition
of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify
the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide.
For further information, please see the Company's website: www.trinitybiotech.com.
.